Trials / Unknown
UnknownNCT05333809
Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer
Explore the Efficacy and Safety of Pembrolizumab and Disitamab Vedotin in HER2 Expressing Metastatic Colorectal Cancer Failed at Least Two Lines of Systemic Treatment
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multi-center, phase Ⅱ study. This study will evaluate the efficacy and safety of pembrolizumab in combination with disitamab vedotin in subject with HER2-expressing metastatic Colorectal Cancer (mCRC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | an anti-PD-1 monoclonal antibody |
| DRUG | Disitamab vedotin | HER2-ADC |
Timeline
- Start date
- 2022-07-01
- Primary completion
- 2024-07-01
- Completion
- 2025-07-01
- First posted
- 2022-04-19
- Last updated
- 2022-04-20
Source: ClinicalTrials.gov record NCT05333809. Inclusion in this directory is not an endorsement.